To analyze patent and design right strategies across different categories of digital therapeutics (DTx) and understand the implications for innovation and development, emphasizing the importance of strategic IP protection.
Key Findings:
Half of app-based DTx lacked patent applications, often relying on platform technologies, which may hinder innovation.
All app + device-based DTx had patents covering programs, biometric acquisition, and platform technology, indicating a robust IP strategy.
Entertainment-based DTx had the highest average number of patent applications, suggesting a trend towards innovation in this category.
Only five of the 30 products were protected by design rights, which were limited in scope, highlighting a potential gap in IP protection.
Interpretation:
Distinct differences in patenting approaches were observed among DTx types, indicating that optimal IP strategies vary by product architecture.
Limitations:
Focus was limited to patents and design rights, excluding copyrights and trade secrets, which may provide a more comprehensive view of IP strategies.
Analysis was based on a specific set of DTx products, which may not represent the entire market, potentially limiting the applicability of the findings.
Conclusion:
Understanding the variations in IP strategies is essential for promoting innovation in digital therapeutics.
Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.
